LCGC International’s Post

Easily measure and quantify the effects of a new drug, cell or gene therapy with an efficient real-time workflow and unlock the true potential of your research by capturing crucial, information rich, biological insights. Learn about new applications: https://lnkd.in/dkGFXz_8

[Join us live] 🗓️Join us on December 12th to learn about robust manufacturing of purer AAV gene therapy vectors. 💡 In this webinar comparison of the cation exchange and affinity column will be presented. To address the recent needs the new CIMmultus HR line (HR stands for High Reproducibility) columns with better resolution and narrower acceptance criteria used for the polishing step will be shown. ✏️ Register here: https://lnkd.in/eZJyBnnx #monoliths #purification #AAV #genetherapy #chromatography

Easily measure and quantify the effects of a new drug, cell or gene therapy with an efficient real-time workflow and unlock the true potential of your research by capturing crucial, information rich, biological insights. Discover how now: https://bit.ly/3sSVSJ9

🚀 Navigating the complexities of AAV gene therapy? Join a panel of industry leaders from PROGEN as they shed light on analytical AAV tools, in-process controls, and meeting regulatory criteria. Don't miss this on-demand webinar packed with valuable insights! 🎬 Watch now: https://ow.ly/J1TC50Q2ZEb #AAVAnalytics #GeneTherapyInsights

The new version of RTCA eSight software supports application-specific image analysis including Wound Healing, 3D Spheriod, Dilution Cloning, etc. Real time, application-specific imaging parameters directly provide quantitative and time-dependent assay results. Image analysis could be daunting. Let eSight do it for you!

What's ahead for cell and gene therapy companies in 2024? My colleagues and RSM US LLP's senior analysts for life sciences Adam Lohr and Justin Culbertson describe how the macroeconomy is impacting the industry.

What's ahead for cell and gene therapy companies in 2024? My colleagues and RSM US LLP's senior analysts for life sciences Adam Lohr and Justin Culbertson describe how the macroeconomy is impacting the industry.

How is investment within the cell and gene therapy sector trending in 2024? Our Q1 2024 Data shows it was a strong quarter. 📊 There was $7.1 billion in total investments in Q1 2024, over 50% of total investments for all of 2023. Of that, $6 billion came from the North American region. What does the full picture look like? Dive into our Q1 2024 Sector Data to learn more. ➡ https://lnkd.in/ebJw3Kxi #cellandgenetherapy

Dive into the crucial aspects of cell and gene therapy manufacturing with our latest eBook. Explore class-defining solutions for bioproduction workflows, focusing on achieving optimal culture conditions, ensuring quality, and maintaining consistency. This comprehensive guide features insights from industry experts like Sean Weaner from BioLife Solutions, Inc. and Erik Woods from Ossium Health. 👉 Discover the eBook Now - https://ow.ly/Tu2f50Qs4Wt #CellGeneTherapy #IndustryInsights #advancedtherapies #ATW24